Cost Management Insights: SG&A Expenses for Genmab A/S and Protagonist Therapeutics, Inc.

Navigating SG&A Expenses: A Tale of Two Biotech Companies

In the dynamic world of biotechnology, effective cost management is crucial for sustaining growth and innovation. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of Genmab A/S and Protagonist Therapeutics, Inc. over the past decade. From 2014 to 2023, Genmab A/S has seen a staggering increase in SG&A expenses, growing by over 4,000%, reflecting its aggressive expansion and strategic investments. In contrast, Protagonist Therapeutics, Inc. has maintained a more modest growth in expenses, increasing by approximately 1,700% during the same period. This disparity highlights the differing strategies of these companies in managing operational costs. As Genmab A/S continues to scale its operations globally, its SG&A expenses have surged, peaking at $3.3 billion in 2023. Meanwhile, Protagonist Therapeutics, Inc. has kept its expenses relatively contained, reaching $33.5 million in 2023. Understanding these trends offers valuable insights into the financial strategies of leading biotech firms.